PMID- 30618856
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1664-0640 (Print)
IS  - 1664-0640 (Electronic)
IS  - 1664-0640 (Linking)
VI  - 9
DP  - 2018
TI  - Human Aquaporin 4 Gene Polymorphisms and Haplotypes Are Associated With Serum 
      S100B Level and Negative Symptoms of Schizophrenia in a Southern Chinese Han 
      Population.
PG  - 657
LID - 10.3389/fpsyt.2018.00657 [doi]
LID - 657
AB  - Background: Aquaporin 4 (AQP4) polymorphism may influence the required dosage of 
      antipsychotic drugs. However, the roles of AQP4 polymorphisms in the blood-brain 
      barrier (BBB) and different neuroprotective effects need further exploration. 
      This study aims to investigate whether the gene polymorphisms and haplotype of 
      AQP4 are associated with serum S100 calcium-binding protein B (S100B) level and 
      clinical symptoms in patients with schizophrenia (SCZ). Methods: We recruited 190 
      patients with SCZ. They provided demographic data, completed relevant 
      questionnaires, and submitted samples to test for four AQP4 tag single nucleotide 
      polymorphisms (SNPs) and eight haplotypes. The rating scales of Positive and 
      Negative Syndrome Scale (PANSS), Personal and Social Performance (PSP), the 
      Global Assessment of Functioning (GAF), Clinical Global Impression (CGI) were 
      assessed and serum S100B level were measured repeatedly during antipsychotic 
      treatment at weeks 0 (baseline), 3, 6, and 9. Using generalized estimating 
      equation (GEE) analyses, log-transformed S100B (logS100B) level was tested for 
      associations with haplotype and other dependent variables. Results: 
      Discretization via the median split procedure showed that logS100B level >1.78 or 
      </= 1.78 had the best discriminant validity to stratify the patients into two 
      groups. After 9 weeks of treatment, the serum S100B level was decreased. The TAA 
      haplotype of AQP4 SNPs was associated with increased serum S100B level (p = 
      0.006). The PANSS negative subscale (PANSS-N) (p = 0.001) and Clinical Global 
      Impression-Improvement (CGI-I) (p = 0.003) scores had a positive association with 
      S100B level. Conclusion: Patients with the TAA haplotype of the AQP4 polymorphism 
      are likely to have increased serum S100B level, negative symptoms and poor 
      control of neuroinflammation. A logS100B level >1.78 may be sufficiently specific 
      to predict a higher severity of negative symptoms. Further study including 
      healthy controls and patients with first and recurrent episodes under selective 
      AQP4 modulators will be necessary to explore the profound effects on the 
      treatment of patients with SCZ and may positively influence their overall 
      outcome.
FAU - Wu, Yung-Fu
AU  - Wu YF
AD  - Department of Psychiatry, Beitou Branch, Tri-Service General Hospital, National 
      Defense Medical Center, Taipei, Taiwan.
AD  - Graduate Institute of Medical Science, National Defense Medical Center, Taipei, 
      Taiwan.
FAU - Sytwu, Huey-Kang
AU  - Sytwu HK
AD  - Department of Microbiology and Immunology, National Defense Medical Center, 
      Taipei, Taiwan.
AD  - National Health Research Institutes, Zhunan, Taiwan.
FAU - Lung, For-Wey
AU  - Lung FW
AD  - Graduate Institute of Medical Science, National Defense Medical Center, Taipei, 
      Taiwan.
AD  - Calo Psychiatric Center, Pingtung, Taiwan.
LA  - eng
PT  - Journal Article
DEP - 20181211
PL  - Switzerland
TA  - Front Psychiatry
JT  - Frontiers in psychiatry
JID - 101545006
PMC - PMC6297372
OTO - NOTNLM
OT  - S100 calcium-binding protein B (S100B)
OT  - aquaporin 4 (AQP4)
OT  - haplotype
OT  - schizophrenia (SCZ)
OT  - single nucleotide polymorphism (SNP)
EDAT- 2019/01/09 06:00
MHDA- 2019/01/09 06:01
PMCR- 2018/12/11
CRDT- 2019/01/09 06:00
PHST- 2018/07/18 00:00 [received]
PHST- 2018/11/19 00:00 [accepted]
PHST- 2019/01/09 06:00 [entrez]
PHST- 2019/01/09 06:00 [pubmed]
PHST- 2019/01/09 06:01 [medline]
PHST- 2018/12/11 00:00 [pmc-release]
AID - 10.3389/fpsyt.2018.00657 [doi]
PST - epublish
SO  - Front Psychiatry. 2018 Dec 11;9:657. doi: 10.3389/fpsyt.2018.00657. eCollection 
      2018.